The 2023 designation effectively restricted US compounding pharmacies from preparing these substances under Section 503A of the Federal Food, Drug, and Cosmetic Act
Peptide Vials (Semaglutide, 10 mg each): 8 weeks 1 vial (3 mg total used) 12 weeks 1 vial (7 mg total used) 16 weeks 2 vials (13.8 mg total used) 20 weeks 3 vials (23.4 mg total used with maintenance dosing) Insulin Syringes (U-100): Per week: 1 syringe 8 weeks: 8 syringes 12 weeks: 12 syringes 16 weeks: 16 syringes 20 weeks: 20 syringes Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution
For those wondering about the differences between semaglutide, tirzepatide, and retatrutide , the data shows a clear hierarchy of efficacy forming among incretin-based therapies
BPC-157: Standard shelf life: 28-30 days refrigerated Maximum (if necessary): 45 days, expect 10-15% potency loss Very stable peptide due to short sequence Shows minimal degradation in first month TB-500 (Thymosin Beta-4): Standard shelf life: 28-30 days refrigerated Maximum: 45-60 days, expect 15-20% potency loss Relatively stable in solution Longer peptide chain but still maintains structure well KPV: Standard shelf life: 28-30 days refrigerated Maximum: 30-40 days Tripeptide (very short), highly stable Minimal degradation within first month Recommendation: Follow 28-30 day rule for these healing peptides

Possibly, the consistent endothelium protection during advanced healing processes in different wounds of various tissues, including blood vessels [1,2,1017], associated with the counteraction of the L-NAME-induced disturbances as well as the counteraction of the L-arginine-induced disturbances, obtained with the same BPC 157 dose range [14,15,1826], should likely compete with the prominent endothelium effect of the heparin-impaired endothelial nitric oxide (NO) synthesis [36] as well as warfarin endothelium damage [37]